CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a novel mucosal vaccine for visceral leishmaniasis by bioengineering harmless lactic acid bacteria to express antigens from the Leishmania infantum parasite. The goal is to create an effective and cost-efficient immunization strategy to prevent the disease, particularly in at-risk populatio…
Visceral leishmaniasis (VL), a vector borne disease caused by protozoan parasites of the genus Leishmania, is responsible for significant morbidity and mortality worldwide and constitutes a major public health problem particularly in poorer countries.
There is also recognised risk that the disease may become more prevalent in Europe as a consequence of global warming and migration.
Treatment is prolonged and expensive and has been complicated by the emergence of drug resistant Leishmania.
While…
INSTITUTO DE SALUD CARLOS III
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
